Abstract

Molecular hybridization is one of the frequently used rational drug design strategies to produce novel ligands. The newly created pharmacophores' biological activity is amplified by the molecular hybridization strategy, and the negative effects caused by the separate components is diminished. At three tubulin colchicine receptors, which are reportedly the targets for anticancer therapy, thirty variants of N-1 substituted indolyl chalcone of N-1 substituted 2-Acetyl Benzimidazole were provisionally docked. When combined, a novel scaffold was shown and it has the potential to be a strong tubulin inhibitor. Discovery and development of novel tubulin polymerization inhibitors is an urgent need in clinical research.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call